Congress and the Trump administration are considering proposals to reduce the price of drugs, but there is a strong causal link between current drug prices and revenues on one hand and future drug research and treatments on the other. Policymakers should keep in mind this trade-off between short-term affordability and long-term innovation: Reducing drug revenues today will lead to a decline in future R&D and a decrease in the number of new drug discoveries.